R. McLeod

发表

The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses

Patricia R S Rodrigues, R. Newcombe, R. Stanton, 2022, Journal of Lipid Research.

The SARS-CoV2 envelope is distinct from host membranes, exposes pro-coagulant lipids, and can be inactivated in vivo by surfactant-containing oral rinses.

R. Newcombe, R. Stanton, R. Murphy, 2022, medRxiv.

Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.

S. Halford, G. Acton, H. Wong, 2016, European journal of cancer.

A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Lisa V. Hampson, D. Tuveson, S. Halford, 2018, British Journal of Cancer.

First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors

Rajiv Kumar, U. Banerji, M. Garrett, 2020, Clinical Cancer Research.

Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents.

S. Self, S. Lockhart, W. Hanekom, 2013, Tuberculosis.

The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses

Patricia R S Rodrigues, R. Newcombe, R. Stanton, 2022, Journal of Lipid Research.

Key issues in the clinical development and implementation of TB vaccines in South Africa.

S. Lockhart, W. Hanekom, H. Mahomed, 2012, Tuberculosis.

First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors.

Zoe Backholer, Rajiv Kumar, U. Banerji, 2014 .

A phase I trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma

Lisa V. Hampson, D. Tuveson, S. Halford, 2018 .